Precision Therapeutics (NASDAQ:POAI) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Precision Therapeutics (NASDAQ:POAI) from a hold rating to a buy rating in a research report report published on Tuesday morning, ValuEngine reports.

Shares of Precision Therapeutics stock opened at $2.68 on Tuesday. The company’s fifty day simple moving average is $2.79. Precision Therapeutics has a 52 week low of $2.59 and a 52 week high of $11.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.10 and a quick ratio of 0.08.

A hedge fund recently bought a new stake in Precision Therapeutics stock. Vanguard Group Inc. acquired a new stake in Precision Therapeutics Inc (NASDAQ:POAI) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned about 0.51% of Precision Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 10.89% of the company’s stock.

Precision Therapeutics Company Profile

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.

Recommended Story: Stock Symbols Definition, Examples, Lookup

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit